OPM 101, the leading proprietary program from the Nanocyclix® platform to inhibit RIPK2

A potentially best-in-Class inhibitor of the RIPK2 target in IBD

  • Potentially best-in-Class molecule for RIPK2 target in Phase 1 healthy volunteers
  • First compound of series allowing to derisk the program and to position it in multiple indications

Potential additional positioning on immunotherapy-induced colitis in oncology

 

 

RIPK2, a kinase of the innate immune system, targeted to treat IBD

IBD is one of the autoimmune and inflammatory pathologies, linked to a deregulation of the immune system.

First indications in IBD for RIPK2:

  • Crohn’s disease and ulcerative colitis

Potential to represent a “franchise” target:

  • Other inflammatory and autoimmune diseases
  • Aggressive and metastatic cancers

RIPK2 is part of a complex activated by bacterial infections, with the purpose of killing infected cells to protect the body.

The pathological hyperactivity of this complex gives rise to inflammatory diseases, especially in the colon.

  • 20 to 30% of current reference treatment sales (ENTYVIO sales and its successors) estimated in 2030
  • Blockbuster potential(> 1 Md US$)

 

OPM-101 :  The leading proprietary program from the Nanocyclix® platform to inhibit RIPK2

 

 

OPM-101 phase I healthy volunteers

 

Contact us